Analyzing Neogen (NEOG) & ImmuCell (ICCC)

Neogen (NASDAQ:NEOG) and ImmuCell (NASDAQ:ICCC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Valuation & Earnings

This table compares Neogen and ImmuCell’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neogen $402.25 million 8.05 $63.14 million $1.21 51.41
ImmuCell $10.99 million 3.40 -$2.32 million N/A N/A

Neogen has higher revenue and earnings than ImmuCell.


This table compares Neogen and ImmuCell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neogen 15.88% 11.45% 10.40%
ImmuCell -21.13% -7.65% -5.30%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Neogen and ImmuCell, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neogen 0 3 0 0 2.00
ImmuCell 0 0 0 0 N/A

Neogen currently has a consensus price target of $62.50, suggesting a potential upside of 0.47%. Given Neogen’s higher probable upside, equities analysts clearly believe Neogen is more favorable than ImmuCell.

Insider & Institutional Ownership

87.4% of Neogen shares are held by institutional investors. Comparatively, 13.8% of ImmuCell shares are held by institutional investors. 3.0% of Neogen shares are held by insiders. Comparatively, 17.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Neogen has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.


Neogen beats ImmuCell on 9 of the 10 factors compared between the two stocks.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed, and grain processors and processors; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topical and diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with's FREE daily email newsletter.